Details of Disease

General Information of Disease (ID: DISXQ6WJ)

• Disease Name: Ischemic heart disease
• Disease Class: BA40-BA6Z: Ischemic heart disease
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISXQ6WJ: Ischemic heart disease
• ICD Code:
  ICD-11: ICD-11: BA40-BA6Z
  ICD-10: ICD-10: I20-I25
  ICD-9: ICD-9: 410-414
  Expand ICD-9: 4.10E+14

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 6 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CHS-0214	DM11R0Z	Phase 3	NA	[1]
GS-6615	DMGJQVI	Phase 3	Small molecular drug	[2]
Autologous endothelial progenitor cell therapy	DM31M4V	Phase 2/3	NA	[3]
AC-607	DMFSVP3	Phase 2	Small molecular drug	[4]
Allogeneic/autologous adult mesenchymal stem cell therapy	DMIZCWN	Phase 1/2	NA	[5]
Bone marrow stem cell therapy	DMTHS4K	Phase 1	NA	[6]

This Disease is Treated as An Indication in 2 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CRE-319M2	DMS56M4	Discontinued in Phase 1	NA	[7]
REN-1053	DMD07NG	Terminated	NA	[8]

This Disease is Treated as An Indication in 10 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Anti-miR-199a oligonucleotides	DMA0JP2	Investigative	NA	[9]
DX-2500	DM3BWTM	Investigative	Antibody	[10]
EP-94	DMIWUQJ	Investigative	NA	[9]
FHT-1106	DM3DZSY	Investigative	NA	[9]
Leonurine	DMF36K7	Investigative	Small molecular drug	[9]
MCP-205	DM3RYUZ	Investigative	NA	[11]
MGN-7455	DMJAMNQ	Investigative	NA	[9]
NK-111	DMUYDVN	Investigative	NA	[9]
TAT-120	DML01Y7	Investigative	NA	[12]
Zn-DPA-H	DM93JXS	Investigative	NA	[9]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] ClinicalTrials.gov (NCT02115750) Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA). U.S. National Institutes of Health.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8413).
• [3] MyoCell, a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases. Curr Opin Mol Ther. 2008 Dec;10(6):611-21.
• [4] ClinicalTrials.gov (NCT01602328) A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects. U.S. National Institutes of Health.
• [5] Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol Sin. 2013 Jun;34(6):747-54.
• [6] Clinical pipeline report, company report or official report of Texas Heart Institute.
• [7] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010576)
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000247)
• [9] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [10] Fully Human Monoclonal Antibody Inhibitors of the Neonatal Fc Receptor Reduce Circulating IgG in Non-Human Primates. Front Immunol. 2015; 6: 176.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2225).